LUPUS NEPHRITIS - WORLD HEALTH ORGANIZATION (WHO) CLASS III

Clinical trials for LUPUS NEPHRITIS - WORLD HEALTH ORGANIZATION (WHO) CLASS III explained in plain language.

Never miss a new study

Get alerted when new LUPUS NEPHRITIS - WORLD HEALTH ORGANIZATION (WHO) CLASS III trials appear

Sign up with your email to follow new studies for LUPUS NEPHRITIS - WORLD HEALTH ORGANIZATION (WHO) CLASS III, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New oral drug ONTO1 tested for Hard-to-Treat lupus kidney disease

Disease control Recruiting now

This early-stage study is testing a new oral drug called ONTO1 for people with lupus, including a serious kidney complication called lupus nephritis. The main goal is to find the highest safe dose and see if it helps improve symptoms when taken alongside standard lupus medication…

Matched conditions: LUPUS NEPHRITIS - WORLD HEALTH ORGANIZATION (WHO) CLASS III

Phase: EARLY_PHASE1 • Sponsor: Hospital for Special Surgery, New York • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

LUPUS NEPHRITIS - WORLD HEALTH ORGANIZATION (WHO) CLASS III

Get alerted when new LUPUS NEPHRITIS - WORLD HEALTH ORGANIZATION (WHO) CLASS III trials appear

New oral drug ONTO1 tested for Hard-to-Treat lupus kidney disease